Related Experiment Video
Updated: Jul 18, 2026
10:03
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Inflammatory biomarkers in stable atherosclerosis.
1Cardiovascular Division, Veterans Affairs Boston Health Care System, West Roxbury Campus, Boston, Massachusetts, USA. skinlay@partners.org
The American Journal of Cardiology
|November 28, 2006
Summary
Inflammation is central to atherosclerosis. While inflammatory biomarkers like C-reactive protein (CRP) show promise in research, their clinical use for cardiovascular risk assessment and treatment efficacy requires further study.
Area of Science:
- Cardiovascular Science
- Inflammation Research
- Biomarker Analysis
Background:
- Inflammation plays a critical role in the development and destabilization of atherosclerosis, a precursor to cardiovascular events like myocardial infarction.
- Inflammatory biomarkers offer insights into these processes, with research linking their average levels to clinical event risk.
- Changes in risk factors can alter plasma biomarker concentrations, indicating suppressed inflammation.
Purpose of the Study:
- To review the current understanding and debated clinical utility of inflammatory biomarkers in cardiovascular disease.
- To assess the evidence supporting the use of inflammatory biomarkers for cardiovascular risk stratification and treatment monitoring.
Main Methods:
- Literature review focusing on studies investigating inflammatory biomarkers in atherosclerosis.
- Analysis of research linking biomarker levels to clinical outcomes and the impact of risk factor modification.
- Evaluation of the evidence base for C-reactive protein (CRP) compared to other inflammatory markers.
Main Results:
- Inflammatory biomarkers are valuable research tools for understanding atherosclerotic progression.
- C-reactive protein (CRP) has the most extensive evidence base among inflammatory biomarkers.
- Current evidence is insufficient for universal clinical adoption of inflammatory biomarkers for risk assessment or treatment efficacy.
Conclusions:
- While inflammatory biomarkers provide insights into atherosclerotic inflammation, their role in routine clinical practice remains under investigation.
- No single inflammatory biomarker currently possesses universal support for clinical application in cardiovascular disease management.
- Further research is necessary to establish the definitive clinical value of inflammatory biomarkers.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:38Inflammation
Overview
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...